Form 4: Monopar Therapeutics COO Andrew Cittadine Reports Stock Transactions
SEC Form 4
Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics, reports the acquisition and disposal of common stock and restricted stock units.
Summary
- On March 31, 2025, Andrew Cittadine, the Chief Operating Officer of Monopar Therapeutics, reported transactions involving the company's stock.
- He acquired 1,791 shares of common stock through the vesting and settlement of restricted stock units.
- He also disposed of 744 shares to cover withholding taxes at a price of $36.41 per share.
- Following these transactions, Cittadine directly owns 41,985 shares of Monopar Therapeutics common stock.
- The transactions also involved restricted stock units granted on February 2, 2022, and February 1, 2023, which vest in installments until December 31, 2025, and December 31, 2026, respectively.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing reflects routine transactions related to executive compensation.
Positives
- The acquisition of shares through RSU vesting indicates confidence in the company's future.
Negatives
- The disposal of shares to cover withholding taxes, while standard, slightly reduces the officer's holdings.
Risks
- There are no specific risks mentioned in this document, but insider transactions are always scrutinized by investors.
Industry Context
This filing is a routine disclosure required by the SEC for insider transactions. It provides transparency into the trading activities of company executives.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their executives.
- The vesting schedules for RSUs are typical for executive compensation packages in the biotech industry.
- Similar filings can be observed for executives at comparable companies like BioNTech or Moderna, detailing their stock transactions.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are part of standard executive compensation practices.
Key Dates
| Date | Description |
|---|---|
| February 2, 2022 | Reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. |
| February 1, 2023 | Reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. |
| March 31, 2025 | Date of the reported transactions: acquisition of 1,791 shares via RSU vesting and disposal of 744 shares for tax withholding. |
| April 02, 2025 | Date of signature for the Form 4 filing. |
| December 31, 2025 | Date when the restricted stock units granted on February 2, 2022, will be fully vested. |
| December 31, 2026 | Date when the restricted stock units granted on February 1, 2023, will be fully vested. |
Keywords
Monopar Therapeutics, Andrew Cittadine, MNPR, insider trading, Form 4, restricted stock units, common stock, vesting, COO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.